pISSN 1226-6051
eISSN 2508-786X

Fig. 2.

Download original image
Fig. 2.

Meta-analysis of CBMD in the three clinical trials. A. Erenumab 70 mg versus placebo; B. Erenumab 140 mg versus placebo. CBMD = change from baseline in monthly migraine days

Korean J Clin Pharm 2019;29:71-8 https://doi.org/10.24304/kjcp.2019.29.2.71
© 2019 Korean J Clin Pharm